CIA
DNA icon

Concurrent Investment Advisors’s Ginkgo Bioworks DNA Stock Holding History

Concurrent Investment Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-678
Closed -$45.8K – 944
2023
Q4 		$45.8K Buy
+678
New +$41.5K ﹤0.01% 832

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Concurrent Investment Advisors's DNA Position: Q1 2024 in Review

Concurrent Investment Advisors sold out of Ginkgo Bioworks (DNA) in Q1 2024, closing a stake of 678 shares — an estimated $45.8K sold.

Concurrent Investment Advisors first reported a position in DNA in Q4 2023 and held it in 1 quarter. The position peaked at $45.8K in Q4 2023. 342 funds tracked by Wall St. Rank hold DNA as of Q1 2024.

  • Concurrent Investment Advisors reported no remaining Ginkgo Bioworks position as of Q1 2024 after selling out during the quarter.
  • Concurrent Investment Advisors sold 678 Ginkgo Bioworks shares in Q1 2024, an estimated $45.8K.
  • Concurrent Investment Advisors first reported a position in Ginkgo Bioworks in Q4 2023 and held it in 1 quarter.
  • Concurrent Investment Advisors's Ginkgo Bioworks position peaked at $45.8K in Q4 2023.
  • 342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2024.

Based on Concurrent Investment Advisors's 13F filing for Q1 2024, filed 7 May 2024.